Cybin (NYSEAMEX: CYBN), a biopharmaceutical company focused on advancing psychedelics to therapies, has received approval for first-in-human dosing of its proprietary molecule CYB004. This marks a major milestone as it is the first time a deuterated N,N-dimethyltryptamine (DMT) molecule will be evaluated in humans. 

The Phase 1 CYB004-E trial, the largest ever DMT trial, is being conducted in the Netherlands. Preclinical studies show that CYB004 has improved bioavailability and a longer duration of effect compared to DMT, offering the potential for more convenient dosing methods. Cybin has secured a U.S. patent for CYB004, which provides protection until 2041.

The Company plans to evaluate CYB004 for the treatment of generalized anxiety disorder with or without major depressive disorder.

Doug Drysdale, Cybin’s Chief Executive Officer stated: “The ability to evaluate our novel CYB004 molecule in humans at this early stage is a significant achievement in clinical development and will provide important insight into the pharmacokinetic and pharmacodynamic properties of CYB004 in addition to what we have already learned through our study of DMT.”

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues.

Shares of Cybin trade on the NYSE under the ticker symbol CYBN.